Clinical Trial Update: Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating using adalimumab serum concentration to guide selection of a subsequent biological DMARD in patients with rheumatoid arthritis who fail…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Reade Rheumatology Research Institute | Conditions: Rheumatoid Arthritis | Phase 4 | Status: UNKNOWN